COMPLETED

Contingency Management for Cannabis Use for Persons With HIV

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.

Official Title

Feasibility and Impact of 28-days of Monitored Abstinence From Cannabis Use on Symptoms of Distress, Inflammation, and HIV Viral Load

Quick Facts

Study Start:2021-08-01
Study Completion:2025-07-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT04866004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * HIV-positive (confirmed via HIV medication or relevant HIV labs in subject's name)
  2. * Self-report of cannabis use at least once per week in the 6-month period prior to consent
  3. * Provide a positive urine toxicology (UTOX) screen for cannabis
  4. * Not seeking treatment for cannabis use
  5. * Willing to stop using cannabis for 28 days and attend eight study visits over six weeks.
  6. * Ability and willingness to provide inform consent
  7. * English fluency
  1. * Currently receiving treatment for cannabis or other drug use disorder
  2. * Diagnosed or receiving treatment for a current major depressive or anxiety disorder
  3. * Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22)
  4. * Positive UTOX screen for opioids
  5. * Having a medical, psychiatric, occupational, or other condition that, in the judgment of the study physician, would make participation difficult or unsafe.

Contacts and Locations

Principal Investigator

Chukwuemeka N Okafor, PhD, MPH
PRINCIPAL_INVESTIGATOR
The University of Texas Health Science Center at San Antonio

Study Locations (Sites)

Center for Neurobehavioral Research on Addiction
Houston, Texas, 77054
United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229
United States

Collaborators and Investigators

Sponsor: The University of Texas Health Science Center at San Antonio

  • Chukwuemeka N Okafor, PhD, MPH, PRINCIPAL_INVESTIGATOR, The University of Texas Health Science Center at San Antonio

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-08-01
Study Completion Date2025-07-31

Study Record Updates

Study Start Date2021-08-01
Study Completion Date2025-07-31

Terms related to this study

Additional Relevant MeSH Terms

  • Marijuana
  • HIV Infections